Exec Chat: JNJ's Innovation Partnering Strategy Goes Broad And Beyond 'Pinpoint Intervention'
Executive Summary
Medtech's biggest companies are becoming more hands-on in supporting early-stage technologies; their no longer just looking to pick up ready-to-buy assets. Among the most active in this approach is Johnson & Johnson, which has established several vehicles through which it supports and scouts external innovation. Medtech Insight chats with Mirren Mandalia, senior director of new ventures and transactions for medical devices at Johnson & Johnson Innovation, to find out what is driving J&J's technology sourcing strategy and how medtech innovators can work with the diversified health care giant.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.